DPD-Deficancy-The last Part of a year causes deficancy of Energy in a happy way by DPD: Discussions-Presentations-and dialogue with gerate collegues in mutinational conferences/Meetings/ Thx to all of U!#DGHO26#ESMO26#CareOnRareMiddleEast26#desmoid#kidneyCancer#SCCHN
33
philipp ivanyi retweeted
We are part of the Uromigos world Cup and need your support to bring #theranostics to Nashville. Please share, like or comment to collect points and support our team
🇩🇪 Team Germany is bringing innovation to the Uromigos World Cup! ⚽🏆
Two cities, two research teams, and the latest advances in molecular imaging and theranostics for prostate and kidney cancer.
Will their scientific expertise be enough to bring home the cup? 👀
#UromigosLive
philipp ivanyi retweeted
📣 New: ESMO Advanced and Metastatic Prostate Cancer Living Guideline, with recommendations and algorithms from the 2026 CPG, in a mobile friendly interactive format. Prepared by K Fizazi and S Gillessen
🔗 ow.ly/NYmf50Z9jO7
#ClinicalPracticeGuideline #ESMOGuidelines
philipp ivanyi retweeted
ASCO 2026 brought exciting data that will improve outcome for pts globally. Our MIBC organ preservation trial was presented by Nick.I presented cis v Carbo data from DISCUS trial. We saw amazing and exciting data across cancers.Thank you @asco committees for a stimulating meeting
philipp ivanyi retweeted
Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) nej.md/4nWaxvM
#ASCO26 | @ASCO

ALT A two-panel line graph shows overall survival in two populations, comparing darovasertib (blue line) and chemotherapy (gray line) treatments. Panel A depicts the RAS G12 population, while Panel B shows the overall population. Hazard ratios and confidence intervals are detailed in each panel.

ALT This image shows two line graphs titled "Progression-free Survival in the RAS G12 Population" and "Progression-free Survival in the Overall Population." Both graphs compare survival rates over 13 months between two groups: one receiving darovasertib and the other receiving chemotherapy. Accompanying the graphs are tables detailing the number of events and patients at risk for each treatment group.
philipp ivanyi retweeted
Outcomes with enfortumab vedotin rechallenge after disease progression in metastatic #UrothelialCarcinoma. Presentation by @MichalSternsch @MSKCancerCenter. #ASCO26 written coverage by @RKSayyid @UAUrology > bit.ly/4viTUgb @ASCO
philipp ivanyi retweeted
CaboNivo final results in non-clear cell RCC presented by Dr Darren Feldman: ORR 43% in Cohort 1 (papillary, unclassified, tRCC), with a striking 88% ORR in FH-deficient RCC. mPFS 11 mo, mOS 28 mo. No responses in chromophobe RCC. CaboNivo confirmed as a standard 1L option for these rare subtypes. #ASCO26 #RCC @OncoAlert @ASCO @OncBrothers
philipp ivanyi retweeted
Proud of @charlesbnguyen @cityofhope who just gave a phenomenal overview of #papillary #kidneycancer therapy at #ASCO26. He has been building an impressive portfolio of studies at @cityofhopeoc in GU cancers! Great perspectives shown today including data from @DrChoueiri, @tompowles1, @crisuarez08, @scocmem, @AlbigesL, @mzugman, @theNCI & from this very meeting from @DrDarrenFeldman for cabo/nivo.
philipp ivanyi retweeted
EXCEED #ASCO26: LY4101174 = More data on Nectin4/Topo1 ADCs in 86 patients with pretreated advanced UC
. RRs 20% is lower than expected while haem tox was high. Efficacy and toxicity balance doesn’t support further development. Yesterdays data (LY405 same payload/target) has ⬆️ efficacy and is a preferential agent for R3 development IMO. Not all ADCs with matching target and payload are the same.@OncoAlert
philipp ivanyi retweeted
Clear cell RCC sheds low levels of ctDNA, but positivity and ctDNA dynamics are relevant in the adjuvant setting @DrChoueiri #ASCO26. This analysis is with an exome based personalised technique and shows a lack of sensitivity (5-8% ctDNA+ve rate vs 40% radiological relapse rate) but good specificity (almost all ctDNA +ves relapse). Whole genome ctDNA analysis should work work better. There is a future for ctDNA in renal cancer, we’re just not quite there yet IMO.
philipp ivanyi retweeted
THE @ONCOALERT RoundUp🚨 DAY 3 of #ASCO26
🚨For the FULL NEWSLETTER 👉buff.ly/25YHTzM
🔹 #RASolute302: Daraxonrasib became the first RAS-targeted therapy to improve OS in previously treated metastatic pancreatic cancer (13.2 vs 6.6 mo).
🔹 #LIBRETTO: Adjuvant selpercatinib cut recurrence/progression risk by 83% in RET+ early-stage NSCLC.
🔹 #PROTEUS: Perioperative apalutamide improved pathologic response and long-term outcomes in high-risk localized prostate cancer.
🔹 #BREAKWATER: EC + FOLFIRI further expanded frontline options for BRAF V600E mCRC.
🔹 #HorizonCRC01: Trastuzumab rezetecan showed strong activity in refractory HER2+ mCRC.
🔹 #PLUDO: New data inform optimal sequencing of LuPSMA and docetaxel in mCRPC.
🔹 #OBX115: IL-15–engineered TIL therapy achieved a 67% ORR in heavily pretreated melanoma.
🔹 Ultra-low-dose nivolumab + metronomic chemotherapy improved survival and QoL in recurrent/metastatic HNSCC.
🔹 #SARC041: Abemaciclib became the first CDK4 inhibitor to improve PFS in dedifferentiated liposarcoma.
@GIMedOnc
@DrChoueiri
@jamecancerdoc
@Rodrosb
@YannickBuccella
@HHorinouchi
@MarioBalsaMD
@g_mountzios
@OncBrothers
@lungoncdoc
@diegoadiazg
@AnaVManana
@UOzkerim
@declangmurphy
@DrYukselUrun
@DrSpratticus
@tugbawitter
@DrRishabhOnco
@KalantriShreyas
@josemarciofigu1
@nataliagandur
@DraMartinezLago
@ozdogan_md
philipp ivanyi retweeted
Dear Colleagues at #ASCO26
A Great pleasure to bring you from the podium to your feed our amazing GU Faculty Dr. Tom Powles 🇬🇧presenting EV302
With 3.5 years of follow-up, EV plus pembrolizumab continues to demonstrate durable survival benefits over platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. Median overall survival reached 33.6 months versus 15.9 months with chemotherapy, without new safety signals. Notably, two-thirds of patients achieving complete response initially had partial responses, often converting after additional treatment cycles, highlighting the importance of treatment duration in maximizing long-term outcomes.
asco.org/abstracts-presentat…
@tompowles1
@MichvdHeijden
@MattGalsky
@y_loriot
@IyerGopa
@JCensits
@mar_nataliya
@CVulsteke
@KalaSridh
@shilpaonc
@OncoAlert
@nataliagandur @scocmem @AmandaNizamMD @WeOncologists @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen @tompowles1 @AndreaNecchi @cdanicas @AOmlin @crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini @weoncologists
philipp ivanyi retweeted
The 3.5yr OS from EV302 continues to show transformative benefit (HR 0.53 (0.45-0.63)) #ASCO26 for EV/pembro. The landmark OS for the CR population (30%) is ~90%. Median time to CR is 4.5 months (responses mature over time). Response rates of platinum chemo after EVP is 21% (OS 11 months). This should be considered a 2nd line standard. Median duration of EV was 7 months - longer in responders. Optimal duration of EV trials are needed. @OncoAlert
philipp ivanyi retweeted
ASCO 2026 | Tag 1 Niere
Prof. Dr. Peter J. Goebell und PD Dr. Philipp Ivanyi diskutieren die wichtigsten Daten des ersten Kongresstages zum Nierenzellkarzinom – von aktuellen Adjuvanz-Daten bis zur Frage, wie wir Therapieerfolg aus Patientensicht bewerten.
▶️ Jetzt ansehen.
#ASCO26 #Nierenzellkarzinom #Uroonkologie #onkowissenTV
philipp ivanyi retweeted
#REVIEW 🚨
How does #exercise reduce cancer risk? Zhuang et al. propose that physiological adaptation to aerobic activity reshapes adult stem cell behaviour, limiting transformation and tumour initiation
📖⬇️
dlvr.it/TSfZHT
philipp ivanyi retweeted
Duration of response to UGN-102 by age at baseline across 3 clinical trials in patients with recurrent low-grade intermediate risk #BladderCancer. Presentation by @UroDocAsh @UTMDAnderson. #AUA26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4u6FVtI @AmerUrological




















































